Source | No. | Age (years)* | Female (%) | BMI (kg/m2)* | Smoking (Pack-year) | Pre-bronchodilator FEV1% predicted* | FeNO (ppb)* | Positive atopic status (%) | Diagnosis or duration of asthma (years)* |
---|---|---|---|---|---|---|---|---|---|
Barnes 2012 [11] | 65 | 43.4 (18–55)** | 41.53 | NM | ≤10 | NM | NM | 100 | 6.5 (6.29) |
Pettipher 2014 [12] | 125 | 40.4 (11.4) | 70 | NM | < 10 | 71.5 (6.1) | NM | NM | NM |
123 | 39.7 (10.2) | 81 | NM | < 10 | 71.0 (6.2) | NM | NM | NM | |
117 | 38.9 (11.4) | 76 | NM | < 10 | 71.5 (6.9) | NM | NM | NM | |
Singh 2013 [13] | 21 | 31.1 (7.1) | 14.3 | NM | < 10 | 87.4 (12.0) | 32.7 (21.8) | 100 | NM |
Hall (trial 1) 2015 [14] | 77 | 39.1 (11.5) | 53.2 | 27.0 (4.6) | < 10 | 71.4 (7.3) | NM | 75.3 | NM |
83 | 35.1 (11.1) | 50.6 | 25.9 (4.3) | < 10 | 73.3 (7.3) | NM | 78.3 | NM | |
79 | 37.5 (12.2) | 54.4 | 26.5 (4.7) | < 10 | 73.6 (6.9) | NM | 84.8 | NM | |
Hall (trial 2) 2015 [14] | 81 | 41.8 (12.7) | 61.7 | 27.6 (4.1) | < 10 | 72.6 (7.6) | NM | 82.7 | NM |
Bateman 2017 [16] | 201 | 45.2 (12.1) | 59.2 | 28.1 (5.7) | 0 | 64.4 (9.6) | NM | 100 | 20.5 (14.9) |
219 | 45.6 (12.1) | 54.34 | 26.9 (5.0) | 0 | 64.1 (10.1) | NM | 100 | 20.5 (14.9) | |
212 | 43.5 (12.3) | 60.85 | 27.4 (5.5) | 0 | 64.5 (9.7) | NM | 100 | 18.4 (14.0) | |
133 | 45.8 (12.5) | 54.89 | 27.8 (5.0) | 0 | 63.7 (10.5) | NM | 100 | 21.2 (15.0) | |
Busse 2013 [17] | 79 | 44.7 (11.5) | 65.8 | 29.6 (6.2) | < 10 | 68.2 (7.9) | 31.9 (21.4) | 93.7 | 28.0 (14.1) |
79 | 45.0 (11.3) | 58.2 | 32.0 (6.5) | < 10 | 67.1 (7.9) | 30.9 (30.5) | 91.1 | 24.8 (13.2) | |
79 | 44.6 (11.4) | 69.8 | 31.9 (8.0) | < 10 | 66.7 (8.5) | 28.3 (23.2) | 91.1 | 28.9 (14.5) | |
80 | 43.7 (11.4) | 40.0 | 31.4 (7.2) | < 10 | 66.1 (8.9) | 33.5 (31.6) | 95.0 | 27.3 (12.8) | |
Erpenbeck 2016 [18] | 82 | 41 (12.9) | 24 | 28.5 (5.81) | < 10 | 71.5 (7.11) | 32 (NM) | 100 | NM |
Fowler 2017 [19] | 63 | 33.1 (10.9) | NM | 24.2 (2.9) | < 10 | 85.2 (15.0) | NM | NM | NM |
Gonem 2016 [20] | 30 | 50 (17) | 40 | 31.0 (5.9) | NM | 72.5 (23.8) | 30 (24) | 87 | 32 (16) |
Kuna (trial 1) 2016 [21] | 57 | 38.4 (NM) | 16 | 26.3 (NM) | < 10 | 82.6 (NM) | NM | 100 | 13 (NM) |
Kuna (trial 2)2016 [21] | 95 | 43.3 (NM) | 28 | 26.9 (NM) | < 10 | 66.2 (NM) | NM | 72 | 11.1 (NM) |
90 | 43.0 (NM) | 21 | 27.0 (NM) | < 10 | 68.5 (NM) | NM | 77 | 12.1 (NM) | |
92 | 43.5 (NM) | 37 | 27.2 (NM) | < 10 | 69.0 (NM) | NM | 64 | 10 (NM) | |
Wenzel 2014 [22] | 93 | 35 (18–68)** | 49 | 26.0 (19.3–34.6)** | < 10 | 73.4 (60–84)*** | 47.5 (26–244)** | 100 | NM |
Bateman 2018 [23] | 976 | 41.0 (NM) | 49.5 | 27.5 (NM) | ≤10 | NM | NM | 100 | 18.2 (NM) |
Diamant 2014 [24] | 18 | 30.6 (21–46)** | 0 | 25.58 (NM) | < 10 | NM | 51.6 (38.5) | 100 | NM |
Miller 2017 [25] | 108 | 41.1 (12.4) | 53.7 | 28.8 (4.8) | < 10 | 72.8 (7.6) | NM | 63.9 | 28.2 (12.9) |